Journal
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
Volume 24, Issue 4, Pages 533-540Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2011.09.001
Keywords
acute myeloid leukemia; AML; allogeneic; graft versus leukemia; GVL; hematopoietic stem cell transplantation; HSCT; interleukin-2; IL-2; killer immunoglobulin-like receptors; KIR; natural killer; NK; T cell
Categories
Funding
- Intramural NIH HHS [Z99 HL999999] Funding Source: Medline
Ask authors/readers for more resources
Allogeneic hematopoietic stem cell transplantation (HSCT) demonstrated convincingly the potential of allogeneic T cells in causing sustained remissions in high-risk hematologic malignancies. However toxicity of allogeneic HSCT limits its application to a broader group of patients. An improved understanding of NK biology along with mechanisms of natural killer (NK) cell and T-cell-mediated alloreactivity against leukemia has led to several clinical immunotherapeutic strategies that preserve graft versus leukemia (GVL) while minimizing the toxicity of HSCT. Here we review strategies being explored both in HSCT and non-HSCT settings that include an emphasis on two key aspects: (a) Maximizing cytotoxicity of alloreactive cells, ie, NK cells and T cells, and (b) Targeted manipulation of critical pathways in T and NK cells contributing to sustained anti-leukemia effects. (C) 2011 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available